[Drug therapy of primary and secondary pulmonary hypertension]

Phase 1b ATMOS trial of the inhaled sGC activator mosliciguat in patients with PAH/CTEPH.

Thorax·2026

Predictive Power of Pulmonary Artery Stiffness - Right Ventricular Interplay, but not Pulmonary Vascular Resistance, in Mild Pulmonary Hypertension: A PVRI GoDeep meta-registry analysis.

Chest·2026

Pulmonary Hypertension in Patients with Moderate to Severe Hypersensitivity Pneumonitis.

Respiration; international review of thoracic diseases·2026

Sotatercept Rescue Therapy for Acute Right Heart Failure in HIV-Associated PAH.

Pulmonary circulation·2026

Sex Differences in Long-Term Survival of Chronic Obstructive Pulmonary Disease Patients following Initiation of Home Noninvasive Ventilation after Acute Hospitalization due to Respiratory Failure.

Respiration; international review of thoracic diseases·2026

Prognostic Value of Exercise Testing in Patients with Liver Cirrhosis.

Diagnostics (Basel, Switzerland)·2026

[Atrial fibrillation : An overview of the various treatment options].

Herz·2026

Colchicine attenuates myocardial inflammation, endothelial dysfunction, and apoptosis in a rat model of alcohol-related cardiac damage.

Herz·2026

Predicting LDL-cholesterol reduction variability on statin-ezetimibe therapy: insights from "Jena auf Ziel".

Herz·2026

[Management of elevated blood pressure and hypertension : Focus on risk reduction].

Herz·2026

Retrospective analysis of serum low-density lipoprotein cholesterol goal attainment and cardiovascular outcomes in coronary heart disease.

Herz·2026

Clinical applications of artificial intelligence in hypertension management: current evidence and future perspectives.

Herz·2026

Lerodalcibep-liga as an Injectable Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)-Targeted Therapy for Patients With Hypercholesterolemia.

The Annals of pharmacotherapy·2026

Examining physicians' behaviors regarding buprenorphine prescribing for opioid use disorder.

Journal of opioid management·2026

Phospholipases D: An Update on Structure-Function Relationships.

Methods in molecular biology (Clifton, N.J.)·2026

Positive Allosteric GABAA Receptor Modulators Reduce Ethanol Consumption and Acute Functional Tolerance.

Alcohol (Fayetteville, N.Y.)·2026

Differential expression of µ-, δ-, and κ-opioid receptors in muscle afferents from male and female rats.

Molecular pain·2026

Approved Medications for Substance Use Disorders: An Umbrella Review of Systematic Reviews and Completed Phase 3 Randomized Controlled Trials.

CNS drugs·2026

Related Experiment Videos

[Drug therapy of primary and secondary pulmonary hypertension]

Related Concept Videos

Phase 1b ATMOS trial of the inhaled sGC activator mosliciguat in patients with PAH/CTEPH.

Predictive Power of Pulmonary Artery Stiffness - Right Ventricular Interplay, but not Pulmonary Vascular Resistance, in Mild Pulmonary Hypertension: A PVRI GoDeep meta-registry analysis.

Pulmonary Hypertension in Patients with Moderate to Severe Hypersensitivity Pneumonitis.

Sotatercept Rescue Therapy for Acute Right Heart Failure in HIV-Associated PAH.

Sex Differences in Long-Term Survival of Chronic Obstructive Pulmonary Disease Patients following Initiation of Home Noninvasive Ventilation after Acute Hospitalization due to Respiratory Failure.

Prognostic Value of Exercise Testing in Patients with Liver Cirrhosis.

[Atrial fibrillation : An overview of the various treatment options].

Colchicine attenuates myocardial inflammation, endothelial dysfunction, and apoptosis in a rat model of alcohol-related cardiac damage.

Predicting LDL-cholesterol reduction variability on statin-ezetimibe therapy: insights from "Jena auf Ziel".

[Management of elevated blood pressure and hypertension : Focus on risk reduction].

Retrospective analysis of serum low-density lipoprotein cholesterol goal attainment and cardiovascular outcomes in coronary heart disease.

Clinical applications of artificial intelligence in hypertension management: current evidence and future perspectives.

Lerodalcibep-liga as an Injectable Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)-Targeted Therapy for Patients With Hypercholesterolemia.

Examining physicians' behaviors regarding buprenorphine prescribing for opioid use disorder.

Phospholipases D: An Update on Structure-Function Relationships.

Positive Allosteric GABAA Receptor Modulators Reduce Ethanol Consumption and Acute Functional Tolerance.

Differential expression of µ-, δ-, and κ-opioid receptors in muscle afferents from male and female rats.

Approved Medications for Substance Use Disorders: An Umbrella Review of Systematic Reviews and Completed Phase 3 Randomized Controlled Trials.

Related Experiment Videos

[Drug therapy of primary and secondary pulmonary hypertension]

Related Concept Videos

Related Articles